Form 4: Arrowhead Pharmaceuticals Director Acquires Shares Through Restricted Stock Units

Victoria Vakiener, a director at Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock through restricted stock units.

Summary

• Victoria Vakiener, a director of Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock on December 18, 2024.
• The shares were acquired through restricted stock units at a price of $22.99 per share.
• These restricted stock units will vest in one installment on the first anniversary date.
• Following the transaction, Ms. Vakiener directly owns 37,944 shares of Arrowhead Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of a director acquiring shares, which is generally a positive sign of confidence, but not a major event.

Positives

• A director's acquisition of shares can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to stock-based compensation for a company director, which is common in the pharmaceutical industry.

Comparison to Industry Standards

• Stock-based compensation, such as restricted stock units, is a common practice for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of one year is also a typical arrangement for such grants.
• Comparable companies in the biotech space often use similar compensation structures to align the interests of management and shareholders.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates a director's confidence in the company.

Key Dates

Keywords

Arrowhead Pharmaceuticals, Director, Stock Acquisition, Restricted Stock Units, Share Ownership, ARWR, Victoria Vakiener